Comprehensive Serum Profiling for the Discovery of Epithelial Ovarian Cancer Biomarkers
Open Access
- 21 December 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (12) , e29533
Abstract
FDA-cleared ovarian cancer biomarkers are limited to CA-125 and HE4 for monitoring and recurrence and OVA1, a multivariate panel consisting of CA-125 and four additional biomarkers, for referring patients to a specialist. Due to relatively poor performance of these tests, more accurate and broadly applicable biomarkers are needed. We evaluated the dysregulation of 259 candidate cancer markers in serum samples from 499 patients. Sera were collected prospectively at 11 monitored sites under a single well-defined protocol. All stages of ovarian cancer and common benign gynecological conditions were represented. To ensure consistency and comparability of biomarker comparisons, all measurements were performed on a single platform, at a single site, using a panel of rigorously calibrated, qualified, high-throughput, multiplexed immunoassays and all analyses were conducted using the same software. Each marker was evaluated independently for its ability to differentiate ovarian cancer from benign conditions. A total of 175 markers were dysregulated in the cancer samples. HE4 (AUC = 0.933) and CA-125 (AUC = 0.907) were the most informative biomarkers, followed by IL-2 receptor α, α1-antitrypsin, C-reactive protein, YKL-40, cellular fibronectin, CA-72-4 and prostasin (AUC>0.800). To improve the discrimination between cancer and benign conditions, a simple multivariate combination of markers was explored using logistic regression. When combined into a single panel, the nine most informative individual biomarkers yielded an AUC value of 0.950, significantly higher than obtained when combining the markers in the OVA1 panel (AUC 0.912). Additionally, at a threshold sensitivity of 90%, the combination of the top 9 markers gave 88.9% specificity compared to 63.4% specificity for the OVA1 markers. Although a blinded validation study has not yet been performed, these results indicate that alternative biomarker combinations might lead to significant improvements in the detection of ovarian cancer.Keywords
This publication has 33 references indexed in Scilit:
- Challenges Related to Developing Serum-Based Biomarkers for Early Ovarian Cancer DetectionCancer Prevention Research, 2011
- Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial SpecimensCancer Prevention Research, 2011
- A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian CancerCancer Prevention Research, 2011
- HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy AlgorithmBritish Journal of Cancer, 2011
- Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massAmerican Journal of Obstetrics and Gynecology, 2010
- Phase II biomarker trial of a multimarker diagnostic for ovarian cancerJournal of Cancer Research and Clinical Oncology, 2010
- Development and Preliminary Evaluation of a Multivariate Index Assay for Ovarian CancerPLOS ONE, 2009
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer: Design and Baseline Characteristics: A Gynecologic Oncology Group StudyCancer Epidemiology, Biomarkers & Prevention, 2008
- Effects of Blood Collection Conditions on Ovarian Cancer Serum MarkersPLOS ONE, 2007